

# Our commitment to transparency in Canada

At Bristol Myers Squibb (BMS) we take our responsibility as a healthcare partner in Canada seriously. Ultimately, we are accountable to our patients for the trust and confidence they put in us.

In our quest to continuously advance science and provide quality medicines to Canadians, we work with healthcare professionals and healthcare organizations. As a partner in the healthcare system, these collaborations drive scientific advancement, contribute to physician education and support patient care programs designed to enhance health outcomes. Guided by the Innovative Medicines Canada **Code of Ethical Practices**, the industry funds and compensates our healthcare partners for their time and expertise.

Since 2017, BMS has proactively and on a voluntary basis disclosed payments it provides to both healthcare professionals (HCPs) and healthcare organizations (HCOs) as part of our overall commitment to greater transparency and high ethical standards in our business practices.



## OUR PATIENTS

### Are at the center of everything we do

We work together cooperatively with a unifying objective to keep patients at the center of everything we do.

This mindset results in a standard approach to the way we develop, promote, and manufacture our products.



## OUR COLLABORATIONS

### With healthcare professionals

We collaborate with some of the country's foremost medical experts to ensure our medicines meet the needs of our patients.

Here at BMS we are guided by the highest ethical standards, including company policy and the Innovative Medicines Canada's **Code of Ethical Practices**



## OUR COMMITMENT

### To act responsibly on all fronts

We respect the practice of medicine and we support the integrity of the physician patient relationship.

Our actions are for the benefit of the patients we serve around the world, our company, our employees, our shareholders and our communities.

# BMS Voluntary payment disclosure 2023

BMS is disclosing payments made to healthcare professionals (HCPs) and/or organizations (HCOs) in exchange for services and payments made to fund charitable, educational and scientific activities.

## About our reporting practices:



Payment information displayed was collected from:  
**1 January 2023 through 31 December 2023**



Payment Information is captured in aggregate form.



Applicable taxes are included.



BMS has used its reasonable best efforts to capture the most comprehensive data possible according to its knowledge and interpretation of the Voluntary Framework on Disclosure of Payments to HCPs/HCOs.

### FEE FOR HCP SERVICES

TAXES INCLUDED\*

**\$ 1,763,735**

### FUNDING TO HCOs

TAXES INCLUDED\*

**\$ 2,357,154**

### SPONSORSHIP OF HCP TRAVEL

**\$ 0**

## NOTE:

While BMS makes every effort to present accurate and reliable information, BMS makes no warranty and assumes no legal liability or responsibility for the accuracy or completeness of the information contained herein. BMS shall not be liable for damages resulting from the use or misuse of the information contained on this website. Certain links may lead to resources located on servers that are not maintained by BMS or under its control, and such hypertext links are provided as a convenience only. The inclusion of a link does not imply endorsement by or of the referenced site and BMS is not responsible for the contents of or the availability of access to such websites.